CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 172 enrolled
Drug / intervention
Pneumococcal conjugate vaccine GSK1024850A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00792909
NCT00792909Phase 3Completed

Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children

GlaxoSmithKline·interventional·Posted Nov 18, 2008·Updated Dec 14, 2017

In Brief

A Phase 3 clinical trial evaluating Pneumococcal conjugate vaccine GSK1024850A for Infections, Streptococcal. Completed, enrolled 172 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of this study is to assess the immune memory induced by primary and booster vaccination with pneumococcal conjugate vaccine GSK1024850A in the first year of life through evaluation of the immune responses following vaccination with a booster dose of pneumococcal conjugate vaccine GSK1024850A in the fourth year of life and to assess immune responses following vaccination with a single dose of pneumococcal conjugate vaccine GSK1024850A in age-matched unprimed children. The study also aims to assess the antibody persistence in the fourth year of life following primary and booster vaccination with pneumococcal conjugate vaccine GSK1024850A in the first year of life. The study is also designed to evaluate the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following a 2-dose vaccination with pneumococcal conjugate vaccine GSK1024850A in the fourth year of life. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307034)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSlovakia, Sweden
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 18, 2008
Enrollment StartDec 2, 2008
Primary CompletionJul 2, 2009
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 17.6 years ago

Interventions

Pneumococcal conjugate vaccine GSK1024850Abiological

Intramuscular injection, 1 dose

Pneumococcal conjugate vaccine GSK1024850Abiological

Intramuscular injection, 2 doses